Olshan Clients Ronin Trading and SW Investment Management Reach Agreement to Reconstitute Board of Peregrine Pharmaceuticals
Reuters, StreetInsider and other media sources reported on the agreement reached by Olshan clients Ronin Trading and SW Investment Management with Peregrine Pharmaceuticals, Inc. pursuant to which Peregrine’s Board of Directors was reconstituted. Pursuant to the agreement, all four of Peregrine’s long-standing incumbent directors resigned and were replaced with four new independent directors, including three designated by Ronin Trading/SW Investment Management. Following the agreement, Peregrine has a seven-member Board consisting of entirely new directors from when Ronin Trading and SW Investment Management launched their campaign for change in July 2017. Ryan Nebel represents Ronin Trading and SW Investment Management in connection with their investment in Peregrine Pharmaceuticals.